Related Experiment Video

Updated: Jun 23, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Rapamycin inhibits growth of cholangiocarcinoma cells

Toshie Okada1, Tokihiko Sawada, Keiichi Kubota

  • 1Second Department of Surgery, Dokkyo University School of Medicine, Kitakobayashi 880, Mibu, Shimotsuga, Tochigi 321-0293, Japan.

Hepato-Gastroenterology
|May 21, 2009
PubMed
Abstract

Insights

Rapamycin effectively inhibited cholangiocarcinoma cell growth in vitro. A synergistic effect was observed when combined with gemcitabine in most cell lines, suggesting a new therapeutic strategy.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Rapamycin, an immunosuppressive agent, is being investigated for its potential anti-cancer properties.
  • Cholangiocarcinoma (bile duct cancer) remains a challenging malignancy with limited treatment options.

Purpose of the Study:

  • To evaluate the in vitro antineoplastic effect of rapamycin on cholangiocarcinoma.
  • To investigate the impact of rapamycin on key signaling pathways involved in cancer cell growth.
  • To assess the combined effect of rapamycin and gemcitabine on cholangiocarcinoma cell proliferation.

Main Methods:

  • Real-time PCR was used to assess mTOR expression in four cholangiocarcinoma cell lines (TFK1, HuCCT1, NOZW, OZ).
  • Western blotting was employed to analyze changes in Akt, phosphorylated PTEN (pPTEN), and phosphorylated S6 (pS6) expression following rapamycin treatment.
  • The MTT assay was utilized to determine the antiproliferative effects of rapamycin, gemcitabine, and their combination.

Main Results:

  • All tested cholangiocarcinoma cell lines expressed mTOR mRNA.
  • Rapamycin significantly decreased the expression of Akt, pPTEN, and pS6 in all cell lines.
  • Rapamycin demonstrated a dose-dependent inhibition of cholangiocarcinoma cell growth. Gemcitabine showed variable efficacy, but a synergistic antiproliferative effect was observed with the combination in three of the four cell lines.

Conclusions:

  • Rapamycin effectively inhibits the proliferation of cholangiocarcinoma cell lines in vitro.
  • The combination of rapamycin and gemcitabine exhibits a synergistic antiproliferative effect in most tested cholangiocarcinoma cell lines.
  • Rapamycin presents a promising therapeutic strategy for cholangiocarcinoma treatment.

More Related Videos

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...